Last reviewed · How we verify

Sevoflurane / Remifentanil

Technical University of Munich · FDA-approved active Small molecule

Sevoflurane is a volatile anesthetic that depresses central nervous system activity, while remifentanil is an opioid agonist that provides analgesia and enhances anesthesia.

Sevoflurane is a volatile anesthetic that depresses central nervous system activity, while remifentanil is an opioid agonist that provides analgesia and enhances anesthesia. Used for General anesthesia for surgical procedures, Intraoperative analgesia and anesthesia maintenance.

At a glance

Generic nameSevoflurane / Remifentanil
SponsorTechnical University of Munich
Drug classGeneral anesthetic (sevoflurane) + opioid analgesic (remifentanil)
TargetGABA receptors (sevoflurane); mu-opioid receptor (remifentanil)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Sevoflurane acts as a general anesthetic by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling in the CNS, producing unconsciousness and amnesia. Remifentanil is a selective mu-opioid receptor agonist that provides rapid-onset analgesia and synergizes with sevoflurane to deepen anesthesia. Together, this combination is used for balanced general anesthesia during surgery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: